FDA approves Merck’s KEYTRUDA for advanced cervical cancer treatment
Merck, known as MSD outside of the United States and Canada, has received approval from the U.S. Food and Drug Administration (FDA) for KEYTRUDA, its anti-PD-1 therapy. This approval, in combination with chemoradiotherapy (CRT), is for the treatment of patients with International Federation of Gynecology and Obstetrics (FIGO) 2014 Stage III-IVA cervical cancer. The approval […]